Results 1 to 10 of about 477,894 (133)

A Newfangled Synthesis of Integrase Inhibitor Drug Substance Raltegravir Potassium

Asian Journal of Chemistry, 2019
Raltegravir sodium synthesis was achieved from its one of the key starting materials with retro synthetic approach, in which without using its critical starting material chemically known as 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride and which is more unstable during the synthesis of raltegravir potassium.
S. Venkat Rao, Vamsi K. Potluri, Ramesh Babu Potluri   +2 more
semanticscholar   +4 more sources

Quantitative Reverse-phase High-performance Liquid Chromatographic Method for the Quantification of Raltegravir Potassium in Bulk and Dosage Forms

Journal of Young Pharmacists, 2019
Objectives: The aim of this present study is to develop an accurate, precise and linear Reverse-phase High-performance Liquid Chromatographic (RPHPLC) method for the estimation of raltegravir potassium in the bulk and pharmaceutical dosage form. Methods: The chromatographic system employs a reverse phase shim-pack C18 column, (150 x 4.6 mm; 5 μ) using ...
Sonam Patel, Krishnaveni Nagappan, Gouru Santhosh Reddy, Gullapalli Kowmudi   +3 more
semanticscholar   +4 more sources

Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir

Journal of Pharmaceutical Sciences, 2021
Early assessment of pH-dependent drug-drug-interactions (DDIs) for salts of poorly soluble weakly acidic compounds offers various advantages for patient safety, the pharmaceutical industry, and regulatory bodies. Biorelevant media and tests reflecting physiological changes during acid-reducing agent (ARA) co-administration can be used to explore and ...
Domagoj Šegregur, James Mann, Andrea Moir, Εva Karlsson, Jennifer B. Dressman   +4 more
semanticscholar   +4 more sources

Spectrophotometric estimation of raltegravir potassium in tablets.

Indian journal of pharmaceutical sciences, 2014
Ultra violet spectrophotometric estimation of the raltegravir potassium, an integrase inhibitor antiretroviral agent was estimated by Ultra violet absorption maxima method at λmax of 328 nm and UV area under curve method in the wave length range of 323-333 nm.
KG Baheti, HM Nimje, PP Kore, MM Gamepatil   +3 more
europepmc   +5 more sources

Antiretroviral drug-drug interactions: A comparison of online drug interaction databases. [PDF]

J Clin Pharm Ther, 2022
Actual or Potential Drug–drug Interactions Identified. Abstract What is known and objective Antiretrovirals have a high drug interaction potential, which can lead to increased toxicity and/or decreased efficacy. Multiple databases are available to assess drug–drug interactions. The aim of our study was to compare interaction identification for commonly
Drwiega EN, Badowski ME, Michienzi S.
europepmc   +2 more sources

Raltegravir Potassium [PDF]

, 2020

openalex   +2 more sources

Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study

Acta Médica Portuguesa, 2022
Introduction: Although raltegravir has been available since 2007, data are lacking on the Portuguese population living with HIV who initiated this antiretroviral therapy.
Rosário Serrão, Kamal Mansinho, Fernando Maltez, Nuno Marques, Alexandre Carvalho, Rosário Pazos, Alexandra Zagalo, Josefina Mendez, Isabel Neves, Joaquim Oliveira, Patrícia Pacheco, Ricardo Correia de Abreu, Ana Cláudia Miranda, Paula Camacho, Laura Paixão, Joana Almeida   +15 more
doaj   +1 more source

New‐onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection

Journal of Diabetes Investigation, Volume 14, Issue 3, Page 489-493, March 2023., 2023
Human immunodeficiency virus patients receiving antiretroviral therapy can develop immune‐inflammatory reconstitution syndrome. Type 1 diabetes is an autoimmune disease, but type 1 diabetes is rarely reported as immune‐inflammatory reconstitution syndrome.
Maho Taguchi, Noriko Ihana‐Sugiyama, Daisuke Shiojiri, Kazuo Izumi, Michi Kobayashi, Noriko Kodani, Ryotaro Bouchi, Mitsuru Ohsugi, Akiyo Tanabe, Kohjiro Ueki, Hiroshi Kajio   +10 more
wiley   +1 more source

Discovery of New Ligand with Quinoline Scaffold as Potent Allosteric Inhibitor of HIV‐1 and Its Copper Complexes as a Powerful Catalyst for the Synthesis of Chiral Benzimidazole Derivatives, and in Silico Anti‐HIV‐1 Studies

Bioinorganic Chemistry and Applications, Volume 2023, Issue 1, 2023., 2023
In this paper, the novel Schiff base ligand containing quinoline moiety and its novel copper chelate complexes were successfully prepared. The catalytic activity of the final complex in the organic reaction such as synthesis of chiral benzimidazoles and anti‐HIV‐1 activity of Schiff base ligand and the products of this reaction were investigated.
Sabikeh G. Azimi, Ghodsieh Bagherzade, Mohammad Reza Saberi, Zeinab Amiri Tehranizadeh, Jamal Rafique   +4 more
wiley   +1 more source

Mitochondrial changes associated with viral infectious diseases in the paediatric population

Reviews in Medical Virology, Volume 31, Issue 6, November 2021., 2021
Summary Infectious diseases occur worldwide with great frequency in both adults and children, causing 350,000 deaths in 2017, according to the latest World Health Organization reports. Both infections and their treatments trigger mitochondrial interactions at multiple levels: (i) incorporation of damaged or mutated proteins into the complexes of the ...
Sonia Romero‐Cordero, Antoni Noguera‐Julian, Francesc Cardellach, Clàudia Fortuny, Constanza Morén   +4 more
wiley   +1 more source